Active B12 Test Market

Growing B12 Vitamin Deficiency Diseases is driving the market growth

Market CAGR for the active B12 test market is being driven by the rising deficiency diseases of vitamin B12. Due to the rising count of cases of macrocytic Lancia-related conditions, such as folic acid deficiency or vitamin B12 deficiencies among adults across many regions of the world, end-users like physicians, hospitals, and diagnostic laboratories have been paying close attention to the Active B12 Test, a type of blood test.

Over the projected period, this factor is anticipated to fuel regional expansion. In addition, the increasing occurrence of macrocytic Lancia in pregnant women as a result of inadequate dietary intake during pregnancy may potentially feed demand in terms of value & volume.

Furthermore, due to rising consumer awareness of folate insufficiency, pernicious anemia, and the prevalence of macrocytic Lancia in adults, the global market for active b12 tests has been expanding steadily. escalating demand for folic acid food fortification. Thus, driving the Active B12 Test market revenue.

The Global Active B12 Test Market Industry is projected to experience substantial growth over the next decade. With a market value of 3.98 USD Billion in 2024, it is expected to reach 20.9 USD Billion by 2035, reflecting a compound annual growth rate of 16.25% from 2025 to 2035. This growth trajectory indicates a robust demand for active B12 testing, driven by factors such as increased awareness of vitamin deficiencies, advancements in diagnostic technologies, and supportive regulatory frameworks. The market's expansion is indicative of a broader trend towards preventive healthcare and improved nutritional awareness.

Regulatory bodies are increasingly recognizing the importance of nutritional testing, which is positively influencing the Global Active B12 Test Market Industry. Policies that promote routine screening for vitamin deficiencies are being implemented in various countries. This regulatory support encourages healthcare providers to incorporate active B12 testing into standard practice. As a result, the market is likely to experience growth as more individuals gain access to testing services. The alignment of healthcare policies with nutritional health initiatives suggests a promising future for the active B12 testing sector.

The increasing incidence of vitamin B12 deficiency globally is a primary driver for the Global Active B12 Test Market Industry. Factors such as dietary changes, particularly in vegetarian and vegan populations, contribute to this trend. According to health organizations, deficiencies can lead to severe neurological and cognitive issues. As awareness of these health risks grows, healthcare providers are more likely to recommend active B12 testing. This heightened demand is expected to propel the market, with projections indicating a market value of 3.98 USD Billion in 2024, reflecting the urgent need for effective diagnostic solutions.

The aging global population is a crucial factor impacting the Global Active B12 Test Market Industry. Older adults are at a higher risk for vitamin B12 deficiency due to factors such as decreased absorption and dietary limitations. As the demographic of individuals aged 65 and older continues to grow, there is an increasing need for effective screening and diagnostic tools. This trend is likely to drive demand for active B12 testing, as healthcare systems adapt to the needs of an aging population. Consequently, the market is expected to witness substantial growth in the coming years.

Innovations in diagnostic technologies are significantly influencing the Global Active B12 Test Market Industry. The introduction of more accurate and efficient testing methods, such as high-performance liquid chromatography and mass spectrometry, enhances the reliability of B12 assessments. These advancements not only improve patient outcomes but also streamline laboratory processes, making testing more accessible. As healthcare facilities adopt these technologies, the market is poised for growth, with an anticipated compound annual growth rate of 16.25% from 2025 to 2035. This trend underscores the importance of integrating cutting-edge technology in routine diagnostics.

There is a growing emphasis on nutritional health and preventive care, which is driving the Global Active B12 Test Market Industry. Public health campaigns and educational initiatives aimed at informing populations about the importance of vitamin B12 are becoming more prevalent. This increased awareness leads to higher testing rates as individuals seek to understand their nutritional status. Healthcare providers are also more proactive in recommending testing as part of routine health assessments. As a result, the market is expected to expand significantly, with projections indicating a value of 20.9 USD Billion by 2035.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Active B12 Test market area will dominate this market, owing to an rising awareness regarding folate deficiency. In addition, the growing number of macrocytic lancia will boost market growth in this region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Active B12 Test Market Share By Region 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Asia Pacific Active B12 Test market accounts for the second-largest market share owing to the rising development of clinical laboratories as well as the rise in geriatric population. Further, the Chin Active B12 Test market held the largest market share, and the Indian Active B12 Test market was the fastest growing market in the European region

The Europe Active B12 Test Market is expected to grow at the fastest CAGR from 2023 to 2032. The growth is attributed to the increase in healthcare expenditure by the government. Moreover, Germany’s Active B12 Test market held the largest market share, and the UK Active B12 Test market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research & development activities in order to expand their product lines, which will help the Active B12 Test market, grow even more. Market players are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Active B12 Test industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Active B12 Test industry to benefit clients and increase the market sector. In recent years, the Active B12 Test industry has offered some of the most significant advantages to medicine. Major players in the Active B12 Test market, including Axis Shield Diagnostics Ltd., Abbott, Siemens Healthcare Private Limited., DiaSorin S.p.A., F. Hoffmann La Roche Ltd., LifeSpan BioSciences, Inc., Demeditec GmbH, and others, are trying  to increase market demand by investing in research and development operations.

The Italian firm DIESSE Diagnostica Senese Società Benefit S.p.A. manufactures integrated and totally internal in-vitro diagnostic systems. Its main office is in Siena. The company has created, produced, and sold cutting-edge diagnostic systems ever since it was founded in 1980, primarily in the areas of immunodiagnostics and automated ESR measurement. The business has presence over than 100 countries, has three production facilities, and one research facility.

DIESSE is recognised as an example of true "Diagnostics Evolution" because it combines cutting-edge technology, Italian design, and new automated diagnostic detection tools. In October 2022, By the end of November, two new tests for vitamin B12 and folate will have been available, according to DIESSE Diagnostica Senese.

Quantification of vitamin B12 and folate is crucial for determining the reasons of anaemia or neuropathy, assessing some patients' nutritional condition, and determining how well these vitamins are being treated. These additional kits will be accessible on CHORUS systems as mono-tests, enhancing the more than 150 tests currently offered in the instrument's analytic menu.

A company called DiaSorin SpA (DiaSorin) specialises in the research, production, and marketing of systems and kits for in vitro diagnostic reagents. In order to enable automatic diagnostic examination, the company creates reagent kits based on ELISA and CLIA procedures. It is possible to diagnose infectious diseases, bone and mineral problems, endocrinology, hypertension, cancer, gastrointestinal infections, autoimmune disorders, neurological and cardiac diseases, among other conditions, using the company's immunodiagnostic and molecular diagnostics tools.

Distributors and direct sales representatives are how DiaSorin markets its goods. It conducts business throughout Asia, Europe, the Middle East, South Africa, North America, and South America. The headquarters of DiaSorin are in Saluggia, Piemonte, Italy. In July 2021, Luminex Corporation has been acquired by DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) at a price of USD 37.00 per share, equating to a total equity value of roughly USD 1.8 billion.

In addition to strengthening its current offering, DiaSorin will have access to Luminex's multiplexing technology through the acquisition, which will also increase the Group's footprint in the United States.